COST-UTILITY OF TOFACITINIB FOR THE TREATMENT OF SEVERE TO MODERATE RHEUMATOID ARTHRITIS IN PORTUGAL

被引：0
|
作者：
Pinheiro, B. [1 ]
Gouveia, M. [2 ]
Ines, M. [3 ]
Borges, M. [1 ]
机构：
[1] Univ Lisbon, Fac Med, Ctr Estudos Med Baseada Evidencia, Lisbon, Portugal
[2] Catolica Lisbon Sch Business & Econ, Lisbon, Portugal
[3] Labs Pfizer Lda, Lisbon, Portugal
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY5
引用
收藏
页码：S901 / S901
页数：1
相关论文
共 50 条
  • [1] TOFACITINIB FOR THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS
    de Lartigue, J.
    [J]. DRUGS OF TODAY, 2012, 48 (08) : 533 - 543
  • [2] COST-UTILITY OF TOCILIZUMAB MONOTHERAPY IN METHOTREXATE INTOLERANT/CONTRA-INDICATED, MODERATE/SEVERE RHEUMATOID ARTHRITIS PATIENTS IN PORTUGAL
    Monteiro, I
    Cafe, A.
    Encarnacao, R.
    Diamantopoulos, A.
    Dejonckheere, F.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A447 - A447
  • [3] Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea
    Lee, Min-Young
    Park, Sun-Kyeong
    Park, Sun-Young
    Byun, Ji-Hye
    Lee, Sang-Min
    Ko, Su-Kyoung
    Lee, Eui-Kyung
    [J]. CLINICAL THERAPEUTICS, 2015, 37 (08) : 1662 - 1676
  • [4] COST-UTILITY ANALYSIS OF CERTOLIZUMAB PEGOL PLUS METHOTREXATE FOR THE TREATMENT OF MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS IN GREECE
    Tzanetakos, C.
    Maniadakis, N.
    Kourlaba, G.
    Tzioufas, A.
    Goules, A.
    Theodoratou, T.
    Christou, P.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A382 - A382
  • [5] COST-EFFECTIVENESS OF TOFACITINIB COMPARED WITH ADALIMUMAB IN THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN IRAN
    Rezaei, S.
    Taheri, S.
    Tahmasebi, N.
    Peiravian, F.
    Yousefi, N.
    [J]. VALUE IN HEALTH, 2018, 21 : S295 - S296
  • [6] COST-EFFECTIVENESS OF TOFACITINIB FOR PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN CHINA
    Tian, L.
    Guo, Q.
    Xiong, X.
    Wang, L.
    Chen, Y.
    Dong, P.
    Ma, A.
    [J]. VALUE IN HEALTH, 2019, 22 : S241 - S241
  • [7] COST-UTILITY OF USTEKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN COLOMBIA
    Aguirre, A.
    Guerrero, E.
    Hernandez, N.
    Coronell, S.
    Argote, A. C.
    Giraldo, C., V
    Ojeda, C.
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A211 - A211
  • [8] COST-UTILITY OF USTEKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN COLOMBIA
    Ojeda, C.
    Hernandez, N.
    Giraldo, C., V
    Argote, A. C.
    Coronell, S.
    Roa, M.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A124 - A124
  • [9] COST-EFFECTIVENESS ANALYSIS OF TOFACITINIB IN COMBINATION WITH METHOTREXATE IN THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN GREECE
    Kourkoulas, N.
    Athanasakis, K.
    Boubouchairopoulou, N.
    Chouchouli, K.
    Kyriopoulos, J.
    [J]. VALUE IN HEALTH, 2018, 21 : S294 - S294
  • [10] COST-UTILITY AND BUDGET IMPACT ANALYSIS OF CERTOLIZUMAB PEGOL PLUS METHOTREXATE FOR THE TREATMENT OF MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS IN GREECE
    Maniadakis, N.
    Boumpas, D.
    Kourlaba, G.
    Christou, P.
    Anargiros, I
    Smets, E.
    Purcaru, O.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A310 - A310
12345